Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370214 · ClinicalTrials.gov registry record
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
A clinical trial, sponsored by Actelion.
- Completed
- Registry status
- 3,515
- Enrollment target
NCT00370214: Completed study, sponsored by Actelion.
NCT00370214 is a clinical trial that has completed, run by Actelion. The registered enrollment target is 3,515 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00370214 has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 3,515 participants
- Enrollment target
Study Summary
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,515 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-12 |
What the finished NCT00370214 record still lists
NCT00370214 is an observational study that tracks outcomes without assigning an intervention. Its 3,515 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00370214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00370214 about?
NCT00370214 is a clinical study titled "REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management". The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating insti...
What is the current status of trial NCT00370214?
This trial is currently completed. The enrollment target is 3,515 participants. The study started on 2006-03. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT00370214?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia